Picture Berlin Partner Special Topic Well-trained Professionals 650x100px
Financing › Details

Delfi Diagnostics–Allianz: investment, 202207 financing round Series B totalling $225m incl existing + co-investor AV8 Ventures


Period Period 2022-07-18
  Predecessor Delfi Diagnostics–Allianz: investment, 202101 financing round Series A totalling $100m incl existing + co-investor AV8 Ventures
Organisations Money taker Delfi Diagnostics Inc.
  Money source AV8 Ventures
  Group Allianz (Group)
Products Product liquid biopsy
  Product 2 venture capital
Index term Index term Delfi Diagnostics–SEVERAL: investment, 202207 financing round Series B $225m led by DFJ Growth

Delfi Diagnostics, Inc.. (7/18/22). "Press Release: Delfi Diagnostics Announces $225 Million Series B Financing to Develop Globally Accessible Portfolio of Liquid Biopsy Tests". Baltimore, MD & Palo Alto, CA.

DFJ Growth's Justin Kao Joins Delfi Board of Directors

Delfi Diagnostics, Inc., a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, today announced a Series B funding of $225 million.

This round of financing was led by DFJ Growth with participation from Eli Lilly and Company, Point72, Brown Advisory, Point Field Partners, Initiate Ventures, Open Field Capital, PTX Capital, and all existing investors including Cowen Healthcare Investments, Foresite Capital, Menlo Ventures, OrbiMed, funds and accounts advised by T. Rowe Price Associates, Inc., Northpond Ventures, Samsara BioCapital, Rock Springs Capital, AV8 Ventures, Illumina Ventures, Osage University Partners, and Windham Venture Partners.

"Cancer is a global public health problem and addressing it requires a solution that is accessible around the world," said Victor Velculescu, MD, PhD, Delfi's CEO and Founder. "We believe our approach is uniquely capable of delivering high performing, cost effective, and clinically relevant tests for multiple applications to meet the needs of patients and providers everywhere."

This funding will support the continued development and commercialization of high-quality and accessible blood tests for single cancer early detection, multi-cancer early detection, and treatment monitoring.

"With this financing, Delfi is even better positioned to make high-quality liquid biopsy applications broadly available regardless of geographic and socioeconomic constraints," said Doug Schenkel, Delfi's CFO. "We recognize that a fundraising of this magnitude is a notable achievement and with that comes great responsibility. Our focus on the Delfi mission to save lives through early cancer detection has never been higher."

Delfi's platform is designed to efficiently develop high-quality liquid biopsy applications via a proprietary and uniquely scalable whole genome fragmentation approach. Rather than looking for relatively scarce signs of cancer found in DNA mutations or methylation changes within narrow regions of the genome, Delfi analyzes cell-free DNA fragments across the entire genome. This allows for a single, low-cost, and straightforward lab process for any test developed on the platform. When combined with breakthroughs in machine learning, the Delfi platform can deliver high-performing results for multiple applications.

Delfi is currently validating the technology for early detection of lung and other cancers in a 15,000-person prospective trial called CASCADE-LUNG, and is working with multiple research institutions to develop additional applications including screening for other cancer types, multi-cancer early detection, and treatment monitoring.

"Delfi has made incredible progress in a short amount of time," said DFJ Growth Partner Justin Kao, who joins Delfi's board of directors. "We believe that Delfi's low cost approach is critical to bringing early cancer detection to millions of patients globally. But the most exciting thing about Delfi is its potential to create a next-generation diagnostics company that innovates on data and analytics rather than focusing on ever-more complicated wet lab techniques. Delfi's cutting-edge machine learning enables new products to be built on the same flexible assay, which has the potential to revolutionize the way we detect and manage cancer. I am thrilled to be joining this board to help Delfi fulfill this potential."

About Delfi Diagnostics

Delfi is developing a new class of liquid biopsy tests for early detection based on altered genome-wide fragmentation profiles, also known as "fragmentomes," representing aberrant packaging of DNA in cancer cells. By applying advanced machine learning algorithms, these fragment patterns are detectable at a very low sequencing cost. Delfi ("DNA Evaluation of Fragments for early Interception") is using this technology to develop highly sensitive and specific cancer detection assays intended for wide and cost-effective distribution and adoption.

Record changed: 2023-02-13


Picture Berlin Partner Special Topic HealthCapital Berlin-Brandenburg 650x200px

More documents for Delfi Diagnostics Inc.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Biotech Showcase 2024 San Francisco 650x300px

» top